Valuation: Jazz Pharmaceuticals plc

Market Cap 16.16B 14B 13.12B 11.97B 22.5B 1,541B 22.84B 154B 60.31B 772B 60.67B 59.36B 2,573B P/E 2026 *
17.6x
P/E 2027 * 15.7x
Enterprise Value 17.55B 15.21B 14.25B 13B 24.43B 1,674B 24.81B 168B 65.51B 838B 65.91B 64.47B 2,795B EV / Sales 2026 *
3.73x
EV / Sales 2027 * 3.19x
Free-Float
96.75%
Yield 2026 *
-
Yield 2027 * -
1 day+0.39%
1 week-4.83%
Current month-1.55%
1 month+2.10%
3 months+9.26%
6 months+49.71%
Current year+46.44%
1 week 244.35
Extreme 244.35
261.28
1 month 233.46
Extreme 233.4601
265.04
Current year 156.95
Extreme 156.95
265.04
1 year 115.12
Extreme 115.12
265.04
3 years 95.49
Extreme 95.49
265.04
5 years 95.49
Extreme 95.49
265.04
10 years 86.88
Extreme 86.88
265.04
Manager TitleAgeSince
Chief Executive Officer 54 2025-08-10
Director of Finance/CFO 62 2024-02-29
Chief Tech/Sci/R&D Officer 54 2023-07-31
Director TitleAgeSince
Chairman 62 2003-02-28
Director/Board Member 65 2012-01-17
Director/Board Member 66 2009-12-31
Date Insider Type Main position Quantity % Market Cap.
8/5/26 Free

Director

1,605 0.0026%
8/5/26 Free

Director

1,605 0.0026%
8/5/26 Free

Director

1,605 0.0026%
Change 5-day change 1-year change 3-year change Capi.($)
+0.39%-4.83%+119.66%+78.65% 16.16B
+0.43%+4.31%+90.84%+130.99% 1,088B
+0.41%+1.27%+50.98%+50.05% 629B
-0.53%+1.04%+25.23%+63.46% 440B
-0.30%-0.08%+45.94%+37.59% 359B
-0.42%-1.31%+26.68%+35.88% 291B
-0.43%-1.79%+1.70%+4.71% 245B
+0.45%+2.05%+46.04%+58.54% 225B
+0.08%+2.08%-8.04%-51.61% 204B
+0.07%+3.12%+13.21%+69.84% 168B
Average +0.01%+0.66%+41.22%+47.81% 366.54B
Weighted average by Cap. +0.07%+1.90%+48.97%+66.19%

Financials

2026 *2027 *
Net sales 4.71B 4.08B 3.82B 3.49B 6.55B 449B 6.65B 44.94B 17.57B 225B 17.67B 17.29B 750B 4.97B 4.31B 4.04B 3.68B 6.92B 474B 7.03B 47.49B 18.56B 238B 18.67B 18.27B 792B
Net income 975M 844M 791M 722M 1.36B 92.96B 1.38B 9.31B 3.64B 46.54B 3.66B 3.58B 155B 1.12B 973M 911M 831M 1.56B 107B 1.59B 10.72B 4.19B 53.61B 4.22B 4.12B 179B
Net Debt 1.39B 1.21B 1.13B 1.03B 1.94B 133B 1.97B 13.3B 5.2B 66.54B 5.23B 5.12B 222B -319M -276M -259M -236M -444M -30.43B -451M -3.05B -1.19B -15.24B -1.2B -1.17B -50.81B
Logo Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.
Employees
2,890
Date Price Change Volume
26-08-12 US$248.95 +0.39% 553,511
26-08-11 US$247.98 -3.33% 1,288,298
26-08-10 US$256.52 -0.02% 896,552
26-08-07 US$256.56 -0.04% 970,711
26-08-06 US$256.65 -1.88% 804,491
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
248.94USD
Average target price
281.35USD
Spread / Average Target
+13.02%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. JAZZ Stock